Want to see HK:8189 full AI Analyst Report?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) Price & Analysis

2 Followers

8189 Stock Chart & Stats

HK$0.40

HK$0.00(0.00%)

At close: Jan 09 4:00 PM EST

HK$0.40

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.11 - HK$0.49

Previous CloseN/A

Volume305.00K

Average Volume (3M)1.41M

Market Cap

HK$309.49M

Enterprise ValueHK$361.99M

Total Cash (Recent Filing)HK$29.22M

Total Debt (Recent Filing)HK$109.79M

Price to Earnings (P/E)―

Beta0.47

Next Earnings

Aug 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding1,436,400,000

10 Day Avg. Volume824,500

30 Day Avg. Volume1,413,333

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)46.59

Price to Sales (P/S)1.12

P/FCF Ratio-9.07

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue ReboundA 125% revenue rebound in 2025 signals a meaningful recovery in demand or execution versus prior year. If sustained, higher scale can support improved operating leverage, giving the company a durable runway to spread fixed costs and work toward profitability.

Multi-year Revenue GrowthA multi-year revenue growth rate near 36% implies persistent top-line expansion rather than a one-off spike. Consistent revenue growth provides the structural basis for future margin improvement, reinvestment, and market position strengthening if cost control follows.

Lower Systematic VolatilityA beta around 0.47 indicates lower sensitivity to broad market swings, reflecting potentially steadier operating performance or lower cyclicality. This structural lower volatility can aid access to capital and reduce refinancing risk during stressed market periods.

Bears Say

High And Rising LeverageDebt-to-equity near 9x reflects a materially weakened balance sheet and sharply higher leverage over recent years. Elevated leverage increases interest and refinancing risk, limits strategic flexibility, and can force asset sales or dilutive funding if losses persist.

Persistent Negative Cash FlowConsistent negative operating and free cash flow over multiple years shows the business cannot internally fund operations or growth. This structural cash deficit increases dependence on external financing and heightens liquidity risk absent sustainable margin or working-capital improvements.

Weak Margins And Sustained LossesVery low gross margin and recurring operating and net losses indicate limited pricing power or high input costs. Without structural improvement in margins or cost base, revenue growth alone is unlikely to translate into durable profitability and shareholder value creation.

8189 FAQ

What was Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price range in the past 12 months?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H lowest stock price was HK$0.11 and its highest was HK$0.48 in the past 12 months.

What is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s market cap?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s market cap is HK$309.49M.

When is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s upcoming earnings report date?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s upcoming earnings report date is Aug 11, 2026 which is in 3 days.

How were Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s earnings last quarter?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.043 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.043.

Is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H overvalued?

According to Wall Street analysts Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tianjin TEDA Biomedical Engineering Co. Ltd. Class H pay dividends?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H does not currently pay dividends.

What is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s EPS estimate?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tianjin TEDA Biomedical Engineering Co. Ltd. Class H have?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has 1,436,400,000 shares outstanding.

What happened to Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price movement after its last earnings report?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H reported an EPS of -HK$0.043 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Tianjin TEDA Biomedical Engineering Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:8189

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-16.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H

Tianjin TEDA Biomedical Engineering Company Limited, founded in 2000 and based in Tianjin, People's Republic of China, is a diversified enterprise primarily involved in the research, development, manufacturing, and distribution of biological compound fertilizer products throughout the PRC. Its operations are organized into two main divisions: Biological Compound Fertilizers and Elderly and Health Care Services. The company's agricultural offerings encompass active fertilizers and various tailored blends of nitrogen, phosphorus, and potassium, specifically formulated to promote balanced growth for a range of crops including grains, fruits, and vegetables. Beyond agriculture, Tianjin TEDA Biomedical provides integrated care for the elderly and comprehensive health services. This includes leasing essential equipment for seniors and offering specialized consulting, advisory, and assessment solutions. Furthermore, the company develops and licenses electroencephalography (EEG) diagnosis detection services, utilizing its expertise in EEG technology for diagnostic applications. Its extensive activities also cover the research, development, production, and practical application of biomedical science and technology projects, alongside regional soil resource conditioning and remediation, and the provision of soil environmental quality standards research services.